Joseph M. Jacob, MD

Joseph Jacob, MD, discusses gemcitabine intravesical delivery as a highly effective treatment for high-risk, BCG-unresponsive bladder cancer, achieving an 82% response rate.

Joseph Jacob, MD, discusses the how the recent FDA approval of the gemcitabine intravesical system offers a radically different treatment approach for patients with bladder cancer.

Joseph Jacob, MD, discusses the promising impact of TAR-200.

Joseph Jacob, MD, discusses data from the phase 2b SunRISe-1 study, cohort 2, evaluating TAR-200 in BCG-unresponsive high-risk NMIBC with carcinoma in situ.

Joseph M. Jacob, MD, discusses the key takeaways from the SunRISe-1 study and data presented at the 2024 Genitourinary Cancers Symposium.